[ Network menu | Network entry | Help ]

ENTRY	nt06265
Name	Bladder cancer
Category	Disease view; Cancer
Pathway	hsa05219 Bladder cancer
Disease	H00022 Bladder cancer
Display	drug-target relation   disease type

ERK signaling N00001    EGF → EGFR → GRB2 → SOS → RAS → RAF → MEK → ERK → CCND1 N00006        EGFR* → GRB2 → SOS → RAS → RAF → MEK → ERK N00041        EGFR* → GRB2 → SOS → RAS → RAF → MEK → ERK N00021    EGF → (ERBB2+EGFR) → GRB2 → SOS → RAS → RAF → MEK → ERK N00022    EGF → (ERBB2*+EGFR) → GRB2 → SOS → RAS → RAF → MEK → ERK N00019    FGF → FGFR → GRB2 → SOS → RAS → RAF → MEK → ERK       D1  |                                 N00011        FGFR3* → GRB2 → SOS → RAS → RAF → MEK → ERK → MSK1 → MYC N00077                    HRAS* → RAF → MEK → ERK → MSK1 → MYC N00078                    HRAS* → RAF → MEK → ERK → MSK1 → MYC   Cell cycle N00066    CDKN2A ⊣ MDM2 ⊣ TP53 ⇒ CDKN1A ⊣ (CCND+CDK4/6) → RB1 ⌿ E2F N00067    CDKN2A* ⌿ MDM2 ⊣ TP53 ⇒ CDKN1A ⊣ (CCND+CDK4/6) → RB1 ⌿ E2F N00069                CDKN2A ⊣ (CCND+CDK4/6) → RB1 ⌿ E2F N00071                CDKN2A* ⌿ (CCND+CDK4/6) → RB1 ⌿ E2F N00074                        RB1* ⌿ E2F N00075                        RB1* ⌿ E2F   Transcription N00115    TP53* ⌿ (CDKN1A,GADD45,BAX..

		Drug name
D1	D10927	Erdafitinib (JAN/USAN/INN)